IP Library › Granted Patent US 8,906,371
Granted Patent B2
US 8,906,371 · App. 13/966,185 · Granted Dec 9, 2014

Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,906,371
App. No.
13/966,185
Granted
Dec 9, 2014
Kind
B2
Abstract

This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-γ) and methods for treating IFN-γ mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-γ. Methods of detecting the amount of IFN-γ in a sample using antibodies to IFN-γ are also provided.

Claims (33)

1. An isolated antibody comprising the amino acid sequence of SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14, or SEQ ID NO:30 and/or the amino acid sequence of SEQ ID NO:8, SEQ ID NO:12, SEQ ID NO:16, or SEQ ID NO:31,

wherein the antibody binds to human IFN-γ and

wherein the antibody is produced by a host cell.

2. The antibody of claim 1 , comprising the amino acid sequence of SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14, or SEQ ID NO:30.

3. The antibody of claim 2 , further comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:8, SEQ ID NO:12, SEQ ID NO:16, or SEQ ID NO:31.

4. The antibody of claim 3 , comprising an amino acid sequence at least 98% identical to the amino acid sequence of SEQ ID NO:8, SEQ ID NO:12, SEQ ID NO:16, or SEQ ID NO:31.

5. The antibody of claim 2 , which comprises an amino acid sequence comprising SEQ ID NO:38, SEQ ID NO:39, or SEQ ID NO:40; SEQ ID NO:41 or SEQ ID NO:42; and SEQ ID NO:43 or SEQ ID NO:44.

6. The antibody of claim 3 , comprising an amino acid sequence at least 95% identical to SEQ ID NO:8.

7. The antibody of claim 3 , comprising an amino acid sequence at least 95% identical to SEQ ID NO:12.

8. The antibody of claim 3 , comprising an amino acid sequence at least 95% identical to SEQ ID NO:16.

9. The antibody of claim 3 , comprising an amino acid sequence at least 95% identical to SEQ ID NO:31.

10. The antibody of claim 1 , comprising the amino acid sequence of SEQ ID NO:8, SEQ ID NO:12, SEQ ID NO:16, or SEQ ID NO:31.

11. The antibody of claim 10 , further comprising an amino acid sequence at least 95% identical to SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14, or SEQ ID NO:30.

12. The antibody of claim 11 , comprising an amino acid sequence at least 98% identical to SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14, or SEQ ID NO:30.

13. The antibody of claim 10 , which comprises an amino acid sequence comprising SEQ ID NO:34; SEQ ID NO:35; and SEQ ID NO:36 or SEQ ID NO:37.

14. The antibody of claim 11 , comprising an amino acid sequence at least 95% identical to SEQ ID NO:6.

15. The antibody of claim 11 , comprising an amino acid sequence at least 95% identical to SEQ ID NO:10.

16. The antibody of claim 11 , comprising an amino acid sequence at least 95% identical to SEQ ID NO:14.

17. The antibody of claim 11 , comprising an amino acid sequence at least 95% identical to SEQ ID NO:30.

18. The antibody of claim 2 , further comprising the amino acid sequence of SEQ ID NO:8.

19. The antibody of claim 2 , further comprising the amino acid sequence of SEQ ID NO:12.

20. The antibody of claim 2 , further comprising the amino acid sequence of SEQ ID NO:16.

21. The antibody of claim 2 , further comprising the amino acid sequence of SEQ ID NO:31.

22. The antibody of claim 10 , further comprising the amino acid sequence of SEQ ID NO:6.

23. The antibody of claim 10 , further comprising the amino acid sequence of SEQ ID NO:10.

24. The antibody of claim 10 , further comprising the amino acid sequence of SEQ ID NO:14.

25. The antibody of claim 10 , further comprising the amino acid sequence of SEQ ID NO:30.

26. The antibody of claim 13 , comprising SEQ ID NO:36.

27. The antibody of claim 26 , comprising SEQ ID NO:6 and SEQ ID NO:8.

28. A composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody of claim 2 .

29. A composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody of claim 10 .

30. A composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody of claim 27 .

31. The antibody of claim 1 , wherein the host cell is a CHO cell.

Assignments (5)
MERGER Recorded Jun 2, 2015
From: MEDAREX, L.L.C.
To: E. R. SQUIBB & SONS, L.L.C.
Reel/Frame 035767/0494 →
CHANGE OF NAME Recorded Nov 4, 2014
From: MEDAREX, L.L.C.
To: E.R. SQUIBB & SONS, L.L.C.
Reel/Frame 034096/0880 →
MERGER Recorded Jan 27, 2014
From: MEDAREX, INC.
To: MEDAREX, L.L.C.
Reel/Frame 032049/0357 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2014
From: WELCHER, ANDREW A.; CHUTE, HILARY T.; LI, LUKE; HUANG, HAICHUN
To: AMGEN INC.
Reel/Frame 031870/0982 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2014
From: AMGEN INC.
To: MEDAREX, INC.
Reel/Frame 031871/0021 →